Haber LT, Bradley MA, Buerger AN, Behrsing H, Burla S, Clapp PW, Dotson S, Fisher C, Genco KR, Kruszewski FH, McCullough SD, Page KE, Patel V, Pechacek N, Roper C, Sharma M, and Jarabek AM
The use of in vitro new approach methodologies (NAMs) to assess respiratory irritation depends on several factors, including the specifics of exposure methods and cell/tissue-based test systems. This topic was examined in the context of human health risk assessment for cleaning products at a 1-day public workshop held on 2 March 2023, organized by the American Cleaning Institute ® (ACI). The goals of this workshop were to (1) review in vitro NAMs for evaluation of respiratory irritation, (2) examine different perspectives on current challenges and suggested solutions, and (3) publish a manuscript of the proceedings. Targeted sessions focused on exposure methods, in vitro cell/tissue test systems, and application to human health risk assessment. The importance of characterization of assays and development of reporting standards was noted throughout the workshop. The exposure methods session emphasized that the appropriate exposure system design depends on the purpose of the assessment. This is particularly important given the many dosimetry and technical considerations affecting relevance and translation of results to human exposure scenarios. Discussion in the in vitro cell/tissue test systems session focused on the wide variety of cell systems with varying suitability for evaluating key mechanistic steps, such as molecular initiating events (MIEs) and key events (KEs) likely present in any putative respiratory irritation adverse outcome pathway (AOP). This suggests the opportunity to further develop guidance around in vitro cell/tissue test system endpoint selection, assay design, characterization and validation, and analytics that provide information about a given assay's utility. The session on applications for human health protection emphasized using mechanistic understanding to inform the choice of test systems and integration of NAMs-derived data with other data sources (e.g., physicochemical properties, exposure information, and existing in vivo data) as the basis for in vitro to in vivo extrapolation. In addition, this group noted a need to develop procedures to align NAMs-based points of departure (PODs) and uncertainty factor selection with current human health risk assessment methods, together with consideration of elements unique to in vitro data. Current approaches are described and priorities for future characterization of in vitro NAMs to assess respiratory irritation are noted., Competing Interests: The authors declare that this workshop and the preparation of the workshop proceedings manuscript were funded by the American Cleaning Institute® (ACI). The funder was involved in conceptualization and organization of the workshop, and in a high-level review of the written proceedings. FK was an employee of ACI. KP was an employee of Clorox, a member company of ACI, which manufactures cleaning products and may use the methods/approaches outlined in this manuscript. KG was an employee of Arkema, a member company of ACI, which manufactures chemicals, some of which are used in cleaning products and may use the methods/approaches outlined in this manuscript. CF was an employee of Ecolab, a member company of ACI, which manufactures cleaning products and may use the methods/approaches outlined in this manuscript. NP was an employee of Ecolab at the time of the workshop, and moved to 3M during the preparation of this manuscript. LH, MB, and AB were consultants paid by ACI. LH and MB were employees of the University of Cincinnati. AB was an employee of Stantec ChemRisk at the time of the workshop and moved to ToxStrategies, Inc. during the preparation of this manuscript. HB and VP were employees of the Institute for in vitro Sciences, which uses some of the in vitro experimental models described in this manuscript for commercial purposes. SB was an employee of Invitrolize, which markets in vitro models for the respiratory tract. PC was an employee of the Wake Forest Institute for Regenerative Medicine at the time of the workshop, became an independent consultant during the writing of this manuscript and is now at UNC Chapel Hill. SD was an employee of the Insight Exposure and Risk Sciences Group. AMJ was an employee of the U.S. EPA Office of Research and Development. SDM was an employee of the U.S. EPA Office of Research and Development at the time of the workshop and was an employee of RTI during the writing of the proceedings. CR was the owner of Roper Toxicology Consulting Limited. MS was an advisor to PETA Science Consortium International e.V. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Haber, Bradley, Buerger, Behrsing, Burla, Clapp, Dotson, Fisher, Genco, Kruszewski, McCullough, Page, Patel, Pechacek, Roper, Sharma and Jarabek.)